This is not, however, contradictory with the idea of developing PDE4D selective inhibitors as a potential treatment for Alzheimer’s disease (AD), since more than 20% of individuals diagnosed with AD symptoms do not have amyloid plaque burden and are thus not responsive to antibody therapeutics28. The gene discussed is PDE4D; the disease is Alzheimer disease.